622855-37-2|Wee1 Inhibitor I|4-(2-Chlorophenyl)-9-hydroxypyrrolo[3,4-c]carbazole-1,3-(2H,6H)-dione|-范德生物科技公司

Wee1 Inhibitor I

NMR下载 COA and HPLC MSDS下载
names：
4-(2-Chlorophenyl)-9-hydroxypyrrolo[3,4-c]carbazole-1,3-(2H,6H)-dione
CAS号：
622855-37-2
MDL Number：
MF(分子式)： C20H11ClN2O3 MW(分子量)： 362.76
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	4-(2-Chlorophenyl)-9-hydroxypyrrolo[3,4-c]carbazole-1,3-(2H,6H)-dione
英文别名	Wee1 Inhibitor I; Wee1-Inhibitor I; Wee1-Inhibitor-I; Wee1 Inhibitor-I;
CAS号	622855-37-2
Inchi	InChI=1S/C20H11ClN2O3/c21-13-4-2-1-3-10(13)11-8-15-16(18-17(11)19(25)23-20(18)26)12-7-9(24)5-6-14(12)22-15/h1-8,22,24H,(H,23,25,26)
InchiKey	DPEXRCOBPACFOO-UHFFFAOYSA-N
分子式 Formula	C20H11ClN2O3
分子量 Molecular Weight	362.76
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Wee1 Inhibitor I(CAS:622855-37-2):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Wee1 Inhibitor I is an ATP-binding site-targeting inhibitor of Wee1.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Schmidt M, Rohe A, Platzer C, Najjar A, Erdmann F, Sippl W. Regulation of G2/M Transition by Inhibition of WEE1 and PKMYT1 Kinases. Molecules. 2017 Nov 23;22(12). pii: E2045. doi: 10.3390/molecules22122045. Review. PubMed PMID: 29168755.

[2]Mills CC, Kolb EA, Sampson VB. Recent Advances of Cell-Cycle Inhibitor Therapies for Pediatric Cancer. Cancer Res. 2017 Dec 1;77(23):6489-6498. doi: 10.1158/0008-5472.CAN-17-2066. Epub 2017 Nov 2. Review. PubMed PMID: 29097609; PubMed Central PMCID: PMC5712276.

[3] Brandsma I, Fleuren EDG, Williamson CT, Lord CJ. Directing the use of DDR kinase inhibitors in cancer treatment. Expert Opin Investig Drugs. 2017 Dec;26(12):1341-1355. doi: 10.1080/13543784.2017.1389895. Epub 2017 Oct 14. Review. PubMed PMID: 28984489.

[4] Visconti R, Grieco D. Fighting tubulin-targeting anticancer drug toxicity and resistance. Endocr Relat Cancer. 2017 Sep;24(9):T107-T117. doi: 10.1530/ERC-17-0120. Review. PubMed PMID: 28808045.

[5] Abou Zahr A, Borthakur G. Emerging cell cycle inhibitors for acute myeloid leukemia. Expert Opin Emerg Drugs. 2017 Jun;22(2):137-148. doi: 10.1080/14728214.2017.1330885. Epub 2017 May 22. Review. PubMed PMID: 28506135.

6: Matheson CJ, Backos DS, Reigan P. Targeting WEE1 Kinase in Cancer. Trends Pharmacol Sci. 2016 Oct;37(10):872-881. doi: 10.1016/j.tips.2016.06.006. Epub 2016 Jul 14. Review. PubMed PMID: 27427153.7: Tamura K. Development of cell-cycle checkpoint therapy for solid tumors. Jpn J Clin Oncol. 2015 Dec;45(12):1097-102. doi: 10.1093/jjco/hyv131. Epub 2015 Oct 20. Review. PubMed PMID: 26486823.8: Benada J, Macurek L. Targeting the Checkpoint to Kill Cancer Cells. Biomolecules. 2015 Aug 18;5(3):1912-37. doi: 10.3390/biom5031912. Review. PubMed PMID: 26295265; PubMed Central PMCID: PMC4598780.9: Karantanos T, Theodoropoulos G, Pektasides D, Gazouli M. Clock genes: their role in colorectal cancer. World J Gastroenterol. 2014 Feb 28;20(8):1986-92. doi: 10.3748/wjg.v20.i8.1986. Review. PubMed PMID: 24587674; PubMed Central PMCID: PMC3934468.10: Do K, Doroshow JH, Kummar S. Wee1 kinase as a target for cancer therapy. Cell Cycle. 2013 Oct 1;12(19):3159-64. doi: 10.4161/cc.26062. Epub 2013 Aug 26. Review. PubMed PMID: 24013427; PubMed Central PMCID: PMC3865011.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开